Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SADBE in recurrent herpes labialis
NCT02965781Phase 2Completed
- Sponsor
- Squarex Pharma
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of squaric acid dibutyl ester in herpes labialis (3 arms), sponsored by Squarex Pharma. Primary endpoint: Days to Next Herpes Labialis Episode From 43 Days After the First Dose up to 121 Days After the First Dose. Started Dec 2016; status: completed.
02
Drugs
squaric acid dibutyl ester
03
Conditions
herpes labialis
Beyond the preview
Go deeper on NCT02965781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965781.